Jamie joined Genesys Capital in 2002 and became partner at the firm in 2007 and managing director in 2016. During his tenure with Genesys, he was responsible for investments in twelve early-stage portfolio companies that crossed a multitude of clinical disciplines and technology areas. His current board affiliations include EBT Medical, Fairhaven Pharmaceuticals and Inversago Pharma. His past board affiliations include Allostera Pharma, gIcare Pharma, Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Jamie also volunteers as a board member for BioteCanada, and is an advisor to both the Ontario Genomics Institute (OGI) and the Centre for Commercialization of Regenerative Medicine (CCRM) and is also n associate with Creative Destruction Lab (CDL).
Prior to joining Genesys, Jamie worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided him with significant technical knowledge in many areas of life sciences. Jamie completed a Bachelor of Science (Honours) from Queen’s University and has an MBA from the Rotman School of Management.